Dağtaş Buğra Burç, Erdem Ozan, Güneç Tuğba İlter, Avcı Elif Bal, Manav Vildan, Koku Aksu Ayşe Esra
Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
Department of Dermatology, Medeniyet University Hospital, Istanbul, Turkey.
Dermatol Surg. 2025 May 1;51(5):515-521. doi: 10.1097/DSS.0000000000004528. Epub 2024 Dec 16.
Erythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. Recent studies show that intradermal Botulinum Toxin-A (BoNT-A) is effective for erythema, though objective data are limited.
This study aims to evaluate the efficacy and tolerability of intradermal BoNT-A in patients with ETR.
In this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. Clinician's Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scores were recorded. Erythema and Melanin Index measurements using a Mexameter. Background erythema was assessed through dermatoscopy, while vascular structure and density were evaluated using Investigative Global Assessment (IGA) scores through videocapillaroscopy.
The BoNT-A-treated side demonstrated significant reductions in CEA scores, Erythema Index, and dermatoscopic background erythema, while no significant changes were observed on the saline control side. IGA scores indicated a significant response to treatment on the BoNT-A side. Patient Self-Assessment scores improved on both sides. No serious adverse events requiring hospitalization were reported.
Intradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.
红斑毛细血管扩张型酒渣鼻（ETR）缺乏金标准治疗方法。近期研究表明，皮内注射A型肉毒杆菌毒素（BoNT-A）对红斑有效，不过客观数据有限。
本研究旨在评估皮内注射BoNT-A对ETR患者的疗效和耐受性。
在这项随机、双盲、半脸对照研究中，纳入了30名患者。一侧面部注射用10 mL生理盐水复溶的15单位BoNT-A，对照侧注射生理盐水。在基线和治疗后1个月进行评估。记录临床医生红斑评估（CEA）量表和患者自我评估（PSA）得分。使用Mexameter测量红斑和黑色素指数。通过皮肤镜评估背景红斑，同时通过视频毛细血管镜使用整体调查评估（IGA）分数评估血管结构和密度。
BoNT-A治疗侧的CEA得分、红斑指数和皮肤镜下背景红斑显著降低，而生理盐水对照侧未观察到显著变化。IGA分数表明BoNT-A治疗侧对治疗有显著反应。两侧的患者自我评估得分均有所改善。未报告需要住院治疗的严重不良事件。
皮内注射BoNT-A可有效降低ETR患者的红斑和血管密度，且耐受性良好。
